Recursion Pharmaceuticals (RXRX) has aligned with the US Food and Drug Administration on the design of its phase 3 trial of REC-4881 to treat familial adenomatous polyposis, a genetic condition causing polyps in the colon, the company said Wednesday.
The study is expected to enroll about 200 patients aged at least 18 who have had a colectomy or proctocolectomy. It will evaluate REC-4881 at a dose of 4 milligrams, with the dosing schedule that will be decided based on data emerging from an ongoing trial, Recursion said.
The trial is on track to start in H2 2027, the company said.
Recursion shares were up 4.8% in premarket activity.
Comments